Table 2.
Clinical information on the 47 included patients.
| Parameter | Clinical features | Value |
|---|---|---|
| Clinical presentation (47) a | Tense bullae and blisters | 40(85.11%) |
| Pruritus | 34(72.34%) | |
| Erythema | 30(63.83%) | |
| Skin erosion or rupture | 27(57.45%) | |
| Oral mucosal lesions | 9(19.15%) | |
| Pain | 5(10.64%) | |
| Eczema | 4(8.51%) | |
| Skin lesion distribution (46) a | Whole body | 7(15.22%) |
| Limbs | 36(78.26%) | |
| Trunk | 22(47.83%) | |
| Back | 13(28.26%) | |
| Chest | 11(23.91%) | |
| Abdomen | 5(10.87%) | |
| Face/neck/head/shoulder | 12(26.09%) | |
| Laboratory testing | BP180 or BP180NC16a positive (22) a | 20(90.91%) |
| BP230 positive (11) a | 1(9.10%) | |
| Anti-desmoglein 1 and 3 antibodies positive (4) a | 0(0%) | |
| Eosinophilia (6) a | 2(33.33%) | |
| Leukocytosis (5) a | 1/5(20%) | |
| Skin biopsy | ||
| Epidermis (40) a | Subepidermal blister | 37(92.5%) |
| Subepidermal blister with eosinophil infiltration | 30(75.00%) | |
| Subepidermal blister with neutrophil infiltration | 8(20.00%) | |
| Subepidermal blister with lymphocyte infiltration | 4(10.00%) | |
| Subepidermal blister with fibrin | 2(5.00%) | |
| Chronic inflammation with eosinophils | 1(2.50%) | |
| Spongiosis | 3(7.50%) | |
| Epidermal hyperplasia and edema | 1(2.50%) | |
| Dermis (40) a | Eosinophilic infiltration around the superficial dermis vessels | 20(50.00%) |
| Lymphocyte infiltration around the superficial dermis vessels | 8(20.00%) | |
| Neutrophil infiltration around the superficial dermis vessels | 4(10.00%) | |
| Mononuclear cells infiltration around the superficial dermis vessels | 2(5.00%) | |
| Immunofluorescence | DIF (38) a | |
| IgG and C3 positive | 26(68.42%) | |
| IgG, C3 and C4 positive | 1(2.63%) | |
| IgG, C3 and IgA positive | 2(5.63%) | |
| IgG, C3, IgA and IgM positive | 1(2.63%) | |
| IgG and C3 negative | 2(5.63%) | |
| IgG posive and C3 negative | 1(2.63%) | |
| IgG negative and C3 positive | 1(2.63%) | |
| Unspecific IgG and C3 positive | 2(5.63%) | |
| IgG positive b | 1(2.63%) | |
| C3 positive b | 1(2.63%) | |
| IIF (11) a | ||
| IgG positive | 7(63.64%) | |
| IgG and IgA positive | 1(9.10%) | |
| IgG positive and IgA negative | 1(9.10%) | |
| IgA positive b | 1(9.10%) | |
| IgG negative | 1(9.10%) | |
| Unspecific DIF and IIF (1) | ||
| IgG positive b | 1(100.0%) | |
| Immunohistochemical stain | C3d10 positive (1) | 1(100.0%) |
BP, bullous pemphigoid; DIF, direct immunofluorescence; IIF, indirect immunofluorescence.
a
Indicates the number of 47 patients for whom information on the particular parameter was provided.
b
Other information on DIF or IIF was not available.